The FDA officially recognized EN ISO 10993-1:2025 – “Biological evaluation of medical devices – Part 1: Requirements and general principles for the evaluation of biological safety within a risk management process” on Monday, May 25, 2026. However, the Agency granted only a partial recognition! The 6th edition of ISO 10993-1 has been reshaped with a stronger […]
Environmental Risk Assessment (ERA) is becoming an increasingly central requirement in pharmaceutical development. With the release of the new EMA guideline, regulatory expectations are shifting, and companies need to adapt. Join our 3-part webinar series designed as 30-minute knowledge pills to guide you through the essentials of ERA, with insights from Dr. Chiara Gazerro, regulatory toxicologist. 🔹 ERA Essentials #1 – […]
The Environmental Risk Assessment (ERA) play a key role in regulatory submissions for medicines in the European Union. The European Medicines Agency (EMA) requires a clear, evidence-based process to assess the potential environmental impact of active pharmaceutical ingredients (APIs) that enter the environment through patient use. With the updated EMA guideline (EMEA/CHMP/SWP/4447/00 Rev. 1 – EMA […]
In the rapidly evolving landscape of healthcare, precision medicine has emerged as a groundbreaking approach to tailor medical treatment to the individual characteristics of each patient. At the forefront of this revolution are companion diagnostics (CDx), an integral component of medical devices that holds the key to unlocking personalized and targeted therapies. Let’s explore the […]




